Rigel Pharmaceuticals, Inc., a biotechnology company, engages in the discovery and development of small molecule drugs for the treatment of immune and hematologic disorders, cancer, and rare diseases.
Excellent balance sheet with high growth potential.
Share Price & News
How has Rigel Pharmaceuticals's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: RI2A's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: RI2A underperformed the German Biotechs industry which returned -5.1% over the past year.
Return vs Market: RI2A underperformed the German Market which returned -17.5% over the past year.
Price Volatility Vs. Market
How volatile is Rigel Pharmaceuticals's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Rigel Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: RI2A (€1.42) is trading below our estimate of fair value (€12.04)
Significantly Below Fair Value: RI2A is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: RI2A is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: RI2A is unprofitable, so we can't compare its PE Ratio to the German market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate RI2A's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: RI2A is overvalued based on its PB Ratio (4.9x) compared to the DE Biotechs industry average (3.6x).
How is Rigel Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: RI2A is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (-0.4%).
Earnings vs Market: RI2A is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: RI2A's is expected to become profitable in the next 3 years.
Revenue vs Market: RI2A's revenue (29.3% per year) is forecast to grow faster than the German market (4.2% per year).
High Growth Revenue: RI2A's revenue (29.3% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: RI2A is forecast to be unprofitable in 3 years.
How has Rigel Pharmaceuticals performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: RI2A is currently unprofitable.
Growing Profit Margin: RI2A is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: RI2A is unprofitable, but has reduced losses over the past 5 years at a rate of 0.8% per year.
Accelerating Growth: Unable to compare RI2A's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: RI2A is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (8.7%).
Return on Equity
High ROE: RI2A has a negative Return on Equity (-124.3%), as it is currently unprofitable.
How is Rigel Pharmaceuticals's financial position?
Financial Position Analysis
Short Term Liabilities: RI2A's short term assets ($119.0M) exceed its short term liabilities ($58.2M).
Long Term Liabilities: RI2A's short term assets ($119.0M) exceed its long term liabilities ($35.5M).
Debt to Equity History and Analysis
Debt Level: RI2A's debt to equity ratio (18.2%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if RI2A's debt to equity ratio has reduced over the past 5 years.
Inventory Level: RI2A has a high level of physical assets or inventory.
Debt Coverage by Assets: RI2A's debt is covered by short term assets (assets are 12.1x debt).
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: RI2A has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: RI2A has sufficient cash runway for 1.9 years if free cash flow continues to grow at historical rates of 4.1% each year.
What is Rigel Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate RI2A's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate RI2A's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if RI2A's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if RI2A's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of RI2A's dividend in 3 years as they are not forecast to pay a notable one for the German market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Raul Rodriguez (58yo)
Mr. Raul R. Rodriguez has been the Chief Executive Officer of Rigel Pharmaceuticals, Inc., since November 2014 and has been its President since May 2010. Mr. Rodriguez served as Chief Operating Officer at ...
CEO Compensation Analysis
Compensation vs Market: Raul's total compensation ($USD3.98M) is above average for companies of similar size in the German market ($USD765.33K).
Compensation vs Earnings: Raul's compensation has increased whilst the company is unprofitable.
|Executive VP & CFO||1.83yrs||US$1.19m||0.030% $70.8k|
|Executive VP of Corporate Affairs||17.17yrs||US$1.77m||0.0037% $8.8k|
|Co-Founder||no data||no data||no data|
|VP of Finance & Interim Principal Accounting Officer||2.25yrs||no data||0.000030% $71.6|
|Senior Vice President of Corporate Development||no data||no data||no data|
|Executive Director of Market Access||2.58yrs||no data||no data|
|Executive Vice President of Research||3.5yrs||no data||no data|
|Executive VP & Chief Medical Officer||0.42yr||no data||no data|
|Vice President of Marketing||no data||no data||no data|
Experienced Management: RI2A's management team is considered experienced (2.6 years average tenure).
|Chairman of the Board||5.33yrs||US$208.66k||no data|
|Director and Member of Scientific & Clinical Trial Advisory Committee||23yrs||US$188.66k||0.0013% $3.2k|
|Independent Director||4.75yrs||US$178.16k||no data|
|Independent Director||13.17yrs||US$185.66k||0.0059% $14.2k|
|Director and Member of Scientific & Clinical Trial Advisory Committee||4.58yrs||US$166.16k||no data|
|Director||1yr||no data||no data|
|Independent Director||2.33yrs||US$151.00k||no data|
Experienced Board: RI2A's board of directors are considered experienced (4.7 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 4.3%.
Rigel Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Rigel Pharmaceuticals, Inc.
- Ticker: RI2A
- Exchange: DB
- Founded: 1996
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$264.654m
- Listing Market Cap: US$238.692m
- Shares outstanding: 168.57m
- Website: https://www.rigel.com
Number of Employees
- Rigel Pharmaceuticals, Inc.
- 1180 Veterans Boulevard
- South San Francisco
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|RIGL||NasdaqGS (Nasdaq Global Select)||Yes||Common Stock||US||USD||Nov 2000|
|RI2A||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Nov 2000|
|RI2A||BRSE (Berne Stock Exchange)||Yes||Common Stock||CH||CHF||Nov 2000|
Rigel Pharmaceuticals, Inc., a biotechnology company, engages in the discovery and development of small molecule drugs for the treatment of immune and hematologic disorders, cancer, and rare diseases. The company’s clinical programs include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; and Phase III clinical study for autoimmune hemolytic anemia. Its clinical programs also comprise R835, a proprietary molecule from its interleukin receptor associated kinase (IRAK) program, which is in Phase I clinical study for autoimmune and inflammatory diseases. The company has research and license agreements with Aclaris Therapeutics International Limited for the development and commercialization of janus kinase (JAK) inhibitors for the treatment of alopecia areata and other dermatological conditions; AstraZeneca AB for the development and commercialization of R256, an inhaled JAK inhibitor; BerGenBio AS for the development and commercialization of AXL inhibitors in oncology; and Daiichi Sankyo to pursue research related to MDM2 inhibitors, a novel class of drug targets called ligases, as well as license and supply agreement with Kissei Pharmaceutical Co., Ltd. to develop and commercialize Tavalisse. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is based in South San Francisco, California.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/03/29 21:01|
|End of Day Share Price||2020/03/27 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.